VHCP Management II as of June 30, 2017
Portfolio Holdings for VHCP Management II
VHCP Management II holds 19 positions in its portfolio as reported in the June 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 30.7 | $77M | 1.0M | 74.31 | |
| Biohaven Pharmaceutical Holding | 15.2 | $38M | 1.7M | 22.79 | |
| Ascendis Pharma A S (ASND) | 10.9 | $27M | 987k | 27.76 | |
| Edge Therapeutics | 7.9 | $20M | 1.9M | 10.26 | |
| Dbv Technologies (DBVTF) | 7.6 | $19M | 374k | 50.68 | |
| Ra Pharmaceuticals | 5.8 | $14M | 770k | 18.74 | |
| BioCryst Pharmaceuticals (BCRX) | 5.5 | $14M | 2.5M | 5.56 | |
| Argenx Se (ARGX) | 5.4 | $14M | 647k | 21.04 | |
| Axovant Sciences | 2.8 | $7.0M | 302k | 23.19 | |
| Acceleron Pharma | 1.9 | $4.8M | 157k | 30.39 | |
| Cytomx Therapeutics (CTMX) | 1.8 | $4.5M | 289k | 15.50 | |
| ARCA biopharma | 1.0 | $2.6M | 1.1M | 2.40 | |
| Akari Therapeutics | 0.8 | $2.0M | 426k | 4.61 | |
| Kalvista Pharmaceuticals (KALV) | 0.7 | $1.6M | 222k | 7.36 | |
| Lipocine | 0.6 | $1.6M | 387k | 4.02 | |
| Ocera Therapeutics | 0.6 | $1.4M | 1.2M | 1.16 | |
| Obseva Sa | 0.5 | $1.3M | 150k | 8.55 | |
| Adverum Biotechnologies | 0.3 | $700k | 280k | 2.50 | |
| Sierra Oncology | 0.1 | $153k | 131k | 1.17 |
